We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · May 25, 2022

Serum Levels of Anti-Transcriptional Intermediary Factor 1-γ Autoantibody as Prognostic Markers in Patients With Dermatomyositis

Seminars in Arthritis and Rheumatism


Additional Info

Seminars in Arthritis and Rheumatism
Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis
Semin. Arthritis Rheum. 2022 Apr 21;55(2022)152011, L Zhang, H Yang, H Yang, H Liu, X Tian, W Jiang, Q Peng, G Wang, X Lu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading